The size of the North American Transcatheter Aortic Valve Replacement Market is forecasted to grow USD 1.57 billion by 2021 from USD 0.72 billion in 2021, growing at a CAGR of 16.80% between 2021 to 2026.
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces the improper functioning aortic valves. TAVR offers an efficient valve replacement procedure as compared to open-heart surgery for the benefit of high-risk patients. Transcatheter heart valve replacement systems are referred to as cardiovascular devices that replace the old and damaged valves. TAVR is used to treat aortic valve disorders such as severe aortic stenosis, degeneration, & regurgitation. Transcatheter aortic valve replacement devices are integrated with valve frame (made of nitinol or stainless steel), valve leaflets material (made of bovine or cow heart tissue). These aortic valves are available with varied sizes (such as 14mm, 16mm, 18mm, 20mm, 22mm, & 29mm). TAVR is performed during different surgery methods such as transfemoral implantation (through the femoral artery), transapical implantation (through the apex of the heart), transaortic implantation (through the top of the right chest), and transcranial implantation (through the femoral vein).
The increasing number patient population adopting transcatheter heart valve therapy in the U.S., availability of reimbursement systems for TAVR procedures, a growing number of clinical trials for new products by manufacturers, and rising demand for transcatheter heart valve surgery in Canada are driving the growth of transcatheter aortic valve replacement (TAVR) market in North America.
However, the high cost of the transcatheter aortic valves and certain risks associated with TAVR therapy are expected to restrain the transcatheter aortic valve replacement (TAVR) market in North America.
This research report on the North American TAVR Market has been segmented and sub-segmented into the following categories:
By Surgery Method:
By Valve Material:
By Valve Size:
By Valve Leaflets Material:
By End Users:
By Country:
Regionally, the U.S. accounted for a larger share of the North America Transcatheter Aortic Valve Replacement (TAVR) market in 2019. In contrast, Canada is estimated to grow at a higher CAGR during the forecast period.
Companies playing a dominant role in the North America Transcatheter Aortic Valve Replacement Market profiled in this report are Edwards Lifesciences Corporation (U.S.), Medtronic, Inc. (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), St. Jude Medical Inc. (U.S.), JenaValve Technology, Inc. (Germany), Symetis SA (Switzerland), Direct Flow Medical, Inc. (U.S.), Sorin Group (Italy), Meril Life Sciences India Pvt Ltd (India) and Braile Biomedica (Brazil).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Surgery Method
5.2.1 Introduction
5.2.2 Transfemoral Implantation
5.2.3 Transapical Implantation
5.2.4 Transaortic Implantation
5.2.5 Transcaval Implantation
5.3 Valve Material
5.3.1 Introduction
5.3.2 Nitinol
5.3.3 Stainless Steel
5.3.4 Cobalt-Chromium
5.4 Valve Size
5.4.1 Introduction
5.4.2 14mm to 18 mm
5.4.3 18mm to 22 mm
5.4.4 22mm to 29mm
5.5 Valve Leaflets Material
5.5.1 Introduction
5.5.2 Bovine Heart Tissue
5.5.3 Cow Heart Tissue
5.5.4 Other Valve Leaflets Material
5.6 End Users
5.6.1 Introduction
5.6.2 Hospitals
5.6.3 Ambulatory Surgical Centres
5.6.4 Cardiac Catheterization Laboratories
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Edwards Lifesciences Corporation (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic, Inc. (Ireland)
8.3 Boston Scientific Corporation (U.S.)
8.4 Abbott Laboratories (U.S.)
8.5 St. Jude Medical Inc. (U.S.)
8.6 JenaValve Technology, Inc. (Germany)
8.7 Symetis SA (Switzerland)
8.8 Direct Flow Medical, Inc. (U.S.)
8.9 Sorin Group (Italy)
8.10 Meril Life Sciences India Pvt Ltd (India)
8.11 Braile Biomedica (Brazil)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
